Certara Launches New E-learning Platform for Biosimulation Education

PRINCETON, NJ - Apr 28, 2016 - Certara®, the global biosimulation technology-enabled drug development company, today launched an e-learning platform through Certara University to satisfy the increased need for education in the burgeoning field of biosimulation or model-based drug development. With the addition of this new on-demand content, scientists from all over the world, with differing skill levels in biosimulation, will be able to access the educational assets developed by Certara’s scientific leaders. 

Certara’s gold-standard Phoenix® software, for example, is being used by more than 6,000 scientists in 50 countries, including evolving markets such as China. 

“The use of biosimulation in drug development has evolved from being a research nicety to a regulatory necessity,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “In fact, the U.S. Food and Drug Administration and European Medicines Agency have recommended biosimulation in more than a dozen draft regulatory guidance documents and its use is now expected by regulators. As sponsor companies increase their use of biosimulation to inform pivotal drug development decisions and interact with regulators, ongoing education is becoming of paramount importance to ensure they optimize their application of this technology.”

“Biosimulation’s rapid adoption has created a growing global demand for education in pharmacometrics theory and technologies,” added Nathan Teuscher, Certara’s vice president of scientific training. “We are proud to be expanding Certara University’s reach by providing e-learning classes so we can continue to share our knowledge and experience with drug development researchers around the world in the most effective formats available.”

Certara University now offers four types of educational opportunities:

• In-person, classroom training on pharmacokinetic and pharmacodynamic (PK/PD) theory and Certara’s Phoenix® software technology;
• Customer-specific training programs on PK/PD theory and Certara’s Phoenix software technology;
• Public and private workshops on physiologically-based pharmacokinetic (PBPK) theory and Simcyp® technology;
• On-demand, e-learning courses in PK/PD theory and Certara’s Phoenix software technology.

In addition to the recognized advantages of being able to take a class at the most convenient time with no travel involved, the biosimulation e-learning courses also allow participants to gain access to world-class trainers and learn at their own pace. Applied Cognitive Psychology magazine reports that deeper learning occurs when participants can control the rate at which they move through segmented content. In addition, the Research Institute of America notes that e-learning increases information retention rates by up to 60 percent. This on-demand format also provides standardized delivery, making sure that all participants benefit from a consistent message and style.

To learn more about Certara’s new e-learning courses, please visit www.certarauniversity.com.

About Certara
Certara is a global biosimulation and regulatory writing company, committed to optimizing drug development decisions. Its clients include hundreds of international biopharmaceutical companies, leading academic institutions, and key regulatory agencies. Certara’s solutions, which span drug discovery through patient care, increase the probability of regulatory and commercial success by using the most scientifically-advanced modeling and simulation technologies and regulatory strategies. For more information, visit www.certara.com.